Company / Shareholders' Equity
Corcept Therapeutics Incorporated Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$647.8M
FY2025
5-year range
$371.2M / $679.6M
FY2021-FY2025
Trend
-4.7%
vs FY2024
Sector context
#71 of 213
Health Care
What the data says
At $648M, Corcept Therapeutics Incorporated's shareholders' equity ranks #71 of 213 in the Health Care sector. Shareholders' Equity has fluctuated over the past 10 years, ranging from -$3M in FY2016 to $680M in FY2024.
Based on SEC 10-K filings.
$648M in FY2025 with a 5-year CAGR of +18.6%.
Improved from $507M to $648M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +7.4%
- 5-Year CAGR
- +18.6%
- 10-Year CAGR
- -
Sector benchmark
#71 of 213 in Health CareTop 33% of 213This company $647.8M Sector average $2.5B
▼
-74.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +18.6%, indicating consistent growth.
- In FY2025, shareholders' equity decreased 4.7% year-over-year.
- Ranks #71 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 3.44 (safe zone, above 2.9 threshold)
- Strong profit margin: 20.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $647.8M | -4.7% |
| FY2024 | $679.6M | +34.1% |
| FY2023 | $506.7M | -3.2% |
| FY2022 | $523.3M | +41.0% |
| FY2021 | $371.2M | +34.5% |
| FY2020 | $275.9M | +44.5% |
| FY2019 | $191.0M | +361.5% |
| FY2018 | $41.4M | -78.3% |
| FY2017 | $191.0M | +5736.6% |
| FY2016 | -$3.4M | -118.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026